made in order to more distinctly claim the present invention. Support for the amendment to Claim 1 may be found in Tables 1 and 2, on pages 18 and 19, respectively, as well as on page 8 lines 17-19 of the specification. The specific amendments to the application are shown on a separate set of pages attached hereto and entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment. On this set of pages, the insertions and **[deletions]** are indicated.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/5/01

By: Mark R. Benedict

Mark R. Benedict
Registration No. 44,531
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The paragraph beginning on page 9, line 12, has been deleted and rewritten as follows:

To obtain at least a transgenic non-human animal as a model for neurodegenerative diseases, the natural occurring sequence of the parkin gene in this animal may be replaced on one or both alleles of the chromosomes by a sequence of mPark2, containing mutations or deletions according to the present invention. These animals produce either less or **[more]** less active or no parkin protein.

IN THE CLAIMS:

1. (Twice Amended) An isolated or purified polynucleotide encoding a **[mutant]** mouse parkin2 protein, or a homolog thereof, containing mutations or deletions in at least one of the exons 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, or 12, or containing a frame-shift mutation in exon 4, wherein said **[mutant]** mutation causes Parkinson's disease.

O:\DOCS\CMS\CMS-1340.DOC
053001